Pharmacology, Toxicology and Pharmaceutical Science
Activating Transcription Factor 4
15%
Adult Respiratory Distress Syndrome
15%
Afatinib
8%
Anaplastic Lymphoma Kinase
7%
Anticarcinogen
10%
Breast Cancer
25%
Chronic Obstructive Lung Disease
36%
Cohort Study
7%
Combination Therapy
11%
Cyclin Dependent Kinase 9
9%
Cytotoxicity
13%
Death Receptor 5
15%
Disease
24%
Docetaxel
8%
Drug Repositioning
8%
Elastase
15%
Emphysema
9%
Epidermal Growth Factor Receptor
50%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Erlotinib
11%
Gefitinib
11%
Gemcitabine
9%
Histone
10%
Histone Methyltransferase
16%
Hospital Mortality
13%
Hypovitaminosis D
16%
Leukemia
9%
Liver Cell Carcinoma
11%
Lung Adenocarcinoma
38%
Lung Cancer
23%
Lung Disease
10%
Lung Emphysema
15%
Lysine
8%
Malignant Neoplasm
57%
Mycobacterium Avium Complex
15%
Neoplasm
21%
Non Small Cell Lung Cancer
59%
Overall Survival
13%
Pancreas Cancer
8%
Pemetrexed
24%
Pleura Effusion
10%
Progression Free Survival
28%
Protein Mcl 1
18%
Protein Tyrosine Kinase Inhibitor
13%
Reactive Oxygen Metabolite
20%
Rifampicin
7%
Riluzole
7%
Squamous Cell Lung Carcinoma
15%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
46%
Vitamin D Deficiency
16%
Medicine and Dentistry
Acute Respiratory Distress Syndrome
15%
Cancer Cell
24%
Cell Death
9%
Chronic Obstructive Pulmonary Disease
26%
Computer Assisted Tomography
17%
Connective Tissue Disease
7%
COVID-19
7%
Diagnosis
10%
Disease
13%
Docetaxel
8%
down Regulation
8%
Drug Repositioning
8%
Epidermal Growth Factor Receptor
47%
Epidermal Growth Factor Receptor Kinase Inhibitor
24%
Erlotinib
11%
Exon
9%
Gefitinib
11%
Hazard Ratio
21%
Hospital Mortality
12%
Hypovitaminosis D
16%
Idiopathic Pulmonary Fibrosis
7%
In Vitro
8%
Lung
11%
Lung Adenocarcinoma
31%
Lung Biopsy
9%
Lung Cancer
40%
Lung Nodule
15%
Malignant Neoplasm
13%
Metastatic Carcinoma
9%
Neoplasm
14%
Non Small Cell Lung Cancer
51%
Odds Ratio
8%
Outpatient
8%
Overall Survival
14%
Pleura Effusion
10%
Prognostic Factor
10%
Programmed Cell Death
16%
Progression Free Survival
21%
Proportional Hazards Model
10%
Protein Intake
7%
Silo-Filler's Disease
10%
Skin Metastasis
7%
Smoking
11%
Spirometry
8%
Survivin
7%
Thorax Radiography
7%
Tumor Angiogenesis
7%
Tyrosine-Kinase Inhibitor
16%
Unfolded Protein Response
8%
Vitamin D Deficiency
16%
Biochemistry, Genetics and Molecular Biology
Activating Transcription Factor 4
15%
Adenine
7%
Airflow
7%
Angiogenesis
7%
Apoptosis
12%
B Cell
7%
Bcl-2-Associated X Protein
7%
Calcium Cell Level
7%
Calcium Mobilization
7%
Cancer Cell
100%
Cell Death
20%
Ciclosporin
7%
Circulating Tumor DNA
7%
CRISPR
7%
Cyclin-Dependent Kinase 7
7%
Daunorubicin
7%
down Regulation
33%
Drug Sensitivity
7%
Electronic Health Record
7%
Endoplasmic Reticulum Stress
10%
Epidermal Growth Factor Receptor
15%
Euchromatin
15%
Gemcitabine
9%
Gene Locus
7%
Genome Wide Association Study
7%
Genome-Wide Association Study
7%
Guanosine Triphosphate
7%
Histone Deacetylase
7%
Histone Methyltransferase
12%
Inhibitor of Apoptosis
15%
Insulin-Like Growth Factor 1 Receptor
7%
Lysine
8%
Methyltransferase
7%
Myeloid
15%
Pharmacogenetic Testing
7%
Progression Free Survival
7%
Receptor Tyrosine Kinase Inhibitors
7%
Sensitization
9%
Small Molecule
18%
Smoking
7%
SOX2
7%
Survival Rate
7%
Survivin
7%
TRAIL
31%
Transcriptomics
7%
Tumor Necrosis Factor
70%
Tumor Volume
7%
Unfolded Protein Response
18%
Upregulation
11%
X-Linked Inhibitory Apoptosis Protein
7%